Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model
- PMID: 16957197
- PMCID: PMC1563611
- DOI: 10.1128/AEM.00109-06
Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model
Abstract
Studies showed that specific probiotics might provide therapeutic benefits in inflammatory bowel disease. However, a rigorous screening of new probiotics is needed to study possible adverse interactions with the host, particularly when intended for administration to individuals with certain health risks. In this context, the objective of this study was to investigate the role of three lactobacilli (LAB) on intestinal inflammation and bacterial translocation using variations of the mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced acute colitis. We first compared the in vitro ability of LAB to survive gastrointestinal tract (GIT) conditions and their ability to persist in the GIT of mice following daily oral administration. As a control, we included a nonprobiotic Lactobacillus paracasei strain, previously isolated from an endocarditis patient. Feeding high doses of LAB strains to healthy and to TNBS-treated mice did not induce any detrimental effect or abnormal translocation of the bacteria. Oral administration of Lactobacillus salivarius Ls-33 had a significant preventive effect on colitis in mice, while Lactobacillus plantarum Lp-115 and Lactobacillus acidophilus NCFM did not. None of the three selected LAB strains translocated to extraintestinal organs of TNBS-treated mice. In contrast, L. paracasei exacerbated colitis under severe inflammatory conditions and translocated to extraintestinal organs. This study showed that evaluations of the safety and functionality of new probiotics are recommended. We conclude that not all lactobacilli have similar effects on intestinal inflammation and that selected probiotics such as L. salivarius Ls-33 may be considered in the prevention or treatment of intestinal inflammation.
Figures
Similar articles
-
Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria.Clin Diagn Lab Immunol. 2003 Jul;10(4):696-701. doi: 10.1128/cdli.10.4.696-701.2003. Clin Diagn Lab Immunol. 2003. PMID: 12853407 Free PMC article.
-
Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials.Antonie Van Leeuwenhoek. 1999 Jul-Nov;76(1-4):279-92. Antonie Van Leeuwenhoek. 1999. PMID: 10532384 Review.
-
Probiotic properties of non-conventional lactic acid bacteria: immunomodulation by Oenococcus oeni.Int J Food Microbiol. 2010 Jun 15;140(2-3):136-45. doi: 10.1016/j.ijfoodmicro.2010.04.007. Epub 2010 Apr 10. Int J Food Microbiol. 2010. PMID: 20452078
-
Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide.Gut. 2011 Aug;60(8):1050-9. doi: 10.1136/gut.2010.232918. Epub 2011 Apr 6. Gut. 2011. PMID: 21471573
-
Using murine colitis models to analyze probiotics-host interactions.FEMS Microbiol Rev. 2017 Aug 1;41(Supp_1):S49-S70. doi: 10.1093/femsre/fux035. FEMS Microbiol Rev. 2017. PMID: 28830096 Review.
Cited by
-
Effect of Lactiplantibacillus plantatum HFY11 on Colitis in Mice.Foods. 2024 May 12;13(10):1496. doi: 10.3390/foods13101496. Foods. 2024. PMID: 38790796 Free PMC article.
-
Understanding Ligilactobacillus salivarius from Probiotic Properties to Omics Technology: A Review.Foods. 2024 Mar 15;13(6):895. doi: 10.3390/foods13060895. Foods. 2024. PMID: 38540885 Free PMC article. Review.
-
Lactobacillus acidophilus NCFM and Lactiplantibacillus plantarum Lp-115 inhibit Helicobacter pylori colonization and gastric inflammation in a murine model.Front Cell Infect Microbiol. 2023 Aug 9;13:1196084. doi: 10.3389/fcimb.2023.1196084. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37621875 Free PMC article.
-
Strain-specific alterations in gut microbiome and host immune responses elicited by tolerogenic Bifidobacterium pseudolongum.Sci Rep. 2023 Jan 19;13(1):1023. doi: 10.1038/s41598-023-27706-0. Sci Rep. 2023. PMID: 36658194 Free PMC article.
-
Lactobacillus rhamnosus sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics.BMJ Case Rep. 2022 Jun 28;15(6):e249020. doi: 10.1136/bcr-2022-249020. BMJ Case Rep. 2022. PMID: 35764338 Free PMC article.
References
-
- Altermann, E., W. M. Russell, M. A. Azcarate-Peril, R. Barrangou, B. L. Buck, O. McAuliffe, N. Souther, A. Dobson, T. Duong, M. Callanan, S. Lick, A. Hamrick, R. Cano, and T. R. Klaenhammer. 2005. Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc. Natl. Acad. Sci. USA 102:3906-3912. - PMC - PubMed
-
- Arpi, M., M. Vancanneyt, J. Swings, and J. J. Leisner. 2003. Six cases of Lactobacillus bacteraemia: identification of organisms and antibiotic susceptibility and therapy. Scand. J. Infect. Dis. 35:404-408. - PubMed
-
- Berg, R. D. 1999. Bacterial translocation from the gastrointestinal tract. Adv. Exp. Med. Biol. 473:11-30. - PubMed
-
- Bradley, P. P., D. A. Priebat, R. D. Christensen, and G. Rothstein. 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Investig. Dermatol. 78:206-209. - PubMed
-
- Charteris, W. P., P. M. Kelly, L. Morelli, and J. K. Collins. 1998. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. J. Appl. Microbiol. 84:759-768. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous